Carboprost Tromethamine Injection
- Packing: 0.5 Ml Ampoule, 1 Ml Vial
- Available Strength : 500 mg, 750 mg, 1 gm
Description
Product Description: Carboprost Tromethamine Injection is a meticulously formulated pharmaceutical solution designed to induce uterine contractions and control postpartum hemorrhage. It contains carboprost tromethamine, a synthetic analogue of prostaglandin F2α, known for its potent oxytocic effects. Manufactured to the highest quality standards, this injection offers essential support in obstetric emergencies to prevent excessive bleeding and ensure maternal safety.
Indications and Usage: Carboprost Tromethamine Injection is indicated for the prevention and treatment of postpartum hemorrhage due to uterine atony following childbirth. It is used to induce strong and coordinated uterine contractions to facilitate hemostasis and reduce blood loss in the immediate postpartum period.
Dosage and Administration: The dosage of Carboprost Tromethamine Injection varies depending on the specific clinical scenario and the severity of postpartum hemorrhage. It is typically administered via intramuscular injection under the supervision of a qualified healthcare professional. The recommended dose is 250 mcg, with repeat doses administered at intervals if necessary, up to a maximum of eight doses per day.
Dosage Forms and Strengths: Carboprost Tromethamine Injection is available as a sterile solution in vials containing 250 mcg/mL of carboprost tromethamine formulated for parenteral administration. Each vial is carefully manufactured to ensure accurate dosing and optimal therapeutic outcomes.
Contraindications: This product is contraindicated in patients with a known hypersensitivity to carboprost tromethamine or any of the excipients. It should not be used in patients with active pelvic inflammatory disease, unexplained vaginal bleeding, or a history of hypersensitivity reactions to prostaglandins. Additionally, it is contraindicated in patients with acute respiratory distress syndrome (ARDS) or cardiovascular disease.
Warnings and Precautions: Healthcare providers should exercise caution when administering Carboprost Tromethamine Injection to patients with a history of asthma or other respiratory disorders, as it may induce bronchospasm. Patients should be monitored closely for signs of hypersensitivity reactions, uterine rupture, or excessive uterine contractions. Use in patients with renal or hepatic impairment may require dosage adjustment.
Adverse Reactions/Side Effects: Common adverse reactions associated with Carboprost Tromethamine Injection include nausea, vomiting, diarrhea, and fever. Uterine cramping, abdominal pain, and transient hypertension may also occur. Less common adverse effects include bronchospasm, allergic reactions, and uterine rupture. Patients should be advised to report any unusual symptoms promptly.
Drug Interactions: Concomitant use of Carboprost Tromethamine Injection with other uterotonic agents or drugs that affect uterine contractility may potentiate the effects of carboprost tromethamine or alter its pharmacokinetics. Healthcare providers should review the patient's medication profile carefully to avoid potential drug interactions.
Use In Specific Populations Description: Safety and efficacy of Carboprost Tromethamine Injection in pediatric patients, pregnant women, and nursing mothers have not been established conclusively. Healthcare providers should assess the potential risks and benefits before prescribing this medication in these populations.
How Supplied/Storage and Handling: Carboprost Tromethamine Injection is supplied as a sterile solution in vials for intramuscular injection. It should be stored at controlled room temperature (20°C to 25°C) away from light and moisture. Care should be taken to ensure proper storage and handling to maintain the integrity of the product. Unused portions should be discarded according to standard procedures for biohazardous waste.
